The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis.

BACKGROUND The mature psoriatic lesion does not necessarily demonstrate changes relevant to early phases of the lesion. OBJECTIVE In a model for relapsing psoriasis we examined the epidermal phenotype by means of a panel of immunohistochemical parameters: keratins 14 and 16, epidermal growth factor receptor (EGFR), Ki-67 antigen, and Tdt-mediated Unscheduled Nick End Labeling to detect apoptosis. METHODS In 9 patients, we cleared psoriatic plaques by topical treatment with clobetasol-17-propionate under hydrocolloid occlusion. Relapse (defined as a clinical sum score > or = 6) was awaited. Biopsy specimens of the psoriatic lesion, the cleared skin, the relapsed plaque, and its clinically normal margin were assessed. RESULTS Psoriasis recurred after 19+/-6 weeks (mean +/- SEM). During treatment all parameters improved considerably; however, the number of apoptotic cells was not affected. Ki-67 values decreased well below the normal range. At initial relapse, the symptomless skin adjacent to the relapsing lesion (margin) showed a marked expression of keratin 16 and EGFR. Ki-67 expression was increasing in the margin but was below values of the mature lesion. The localization of cycling cells in the first suprabasal layers was a remarkable feature. Keratin 14 expression was increased in the recurrent lesion itself, but not in the symptomless margin. CONCLUSION Keratin 16 and EGFR expression are early phenomena in the evolution of the lesion, and they anticipate epidermal proliferation. The expression of keratin 14 follows overt epidermal hyperproliferation. The present observation in incipient psoriasis lends support to the hypothesis that the basal cell compartment does not have a primary involvement in the initiation of epidermal abnormalities in psoriasis, but that a coordinated sequence of events involving proliferation and differentiation markers in the first suprabasal layers of the epidermis could be the key to the pathogenesis of this puzzling disease.

[1]  L. Fry,et al.  EFFECT OF PLASTIC OCCLUSIVE DRESSINGS ON PSORIATIC EPIDERMIS , 1970, The British journal of dermatology.

[2]  P. C. van de Kerkhof,et al.  Weekly treatment of psoriasis with a hydrocolloid dressing in combination with triamcinolone acetonide. A controlled comparative study. , 1994, Acta dermato-venereologica.

[3]  James T. Elder,et al.  Overexpression of transforming growth factor alpha in psoriatic epidermis. , 1989, Science.

[4]  S. Friedman Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. , 1987, Archives of dermatology.

[5]  J. Reichrath,et al.  Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. , 1997, Journal of the American Academy of Dermatology.

[6]  A. Cattaneo,et al.  Topical calcipotriol for psoriasis--an immunohistologic study. , 1994, Acta dermato-venereologica. Supplementum.

[7]  P. Brachet,et al.  Cytotoxic effects of 1 alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. , 1996, Cancer letters.

[8]  C. Potten,et al.  Epithelial stem cells in vivo , 1988, Journal of Cell Science.

[9]  I. Campbell,et al.  Keratin expression in normal skin and epidermal neoplasms demonstrated by a panel of monoclonal antibodies , 1992, Journal of cutaneous pathology.

[10]  L. Nanney,et al.  Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. , 1990, The Journal of investigative dermatology.

[11]  E. Lane,et al.  Antibody markers of basal cells in complex epithelia. , 1990, Journal of cell science.

[12]  T. Sun,et al.  Epidermal stem cells. , 1983, The Journal of investigative dermatology.

[13]  P. V. D. van de Kerkhof,et al.  Recruitment of cycling epidermal cells and expression of filaggrin, involucrin and tenascin in the margin of the active psoriatic plaque, in the uninvolved skin of psoriatic patients and in the normal healthy skin. , 1997, Journal of dermatological science.

[14]  P. Kerkhof,et al.  Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream , 1996 .

[15]  L. Nanney,et al.  The EGF/TGFα Receptor in Skin , 1990 .

[16]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[17]  G. Carpenter,et al.  Visualization of epidermal growth factor receptors in human epidermis. , 1984, The Journal of investigative dermatology.

[18]  A. Gottlieb,et al.  Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. , 1990, The Journal of investigative dermatology.

[19]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[20]  G. Priestley Effects of corticosteroids on the growth and metabolism of fibroblasts cultured from human skin , 1978, The British journal of dermatology.

[21]  C. Y. Wang,et al.  Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques , 1986, The Journal of experimental medicine.

[22]  E. Jong,et al.  Markers for proliferation and keratinization in the margin of the active psoriatic lesion , 1990 .

[23]  R. Rothlein,et al.  Kinetics and characterization of intercellular adhesion molecule-1 (ICAM-1) expression on keratinocytes in various inflammatory skin lesions and malignant cutaneous lymphomas. , 1989, Journal of the American Academy of Dermatology.

[24]  K. Hashimoto,et al.  Differential expression of transforming growth factor-alpha (TGF-alpha) and EGF receptor in transitional area of psoriatic epidermis. , 1994, Journal of dermatological science.

[25]  G. Priestley,et al.  Effects of corticosteroids on the proliferation of normal and abnormal human connective tissue cells , 1980, The British journal of dermatology.

[26]  A. Gottlieb,et al.  Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro. , 1992, The Journal of investigative dermatology.

[27]  L. Kemény,et al.  Down-regulation of epidermal growth factor receptors by dithranol. , 1993, Acta dermato-venereologica.

[28]  R. Stoughton,et al.  Mitotic index of psoriatic lesions treated with anthralin, glucocorticosteriod and occlusion only. , 1970, The Journal of investigative dermatology.

[29]  H. Valdimarsson,et al.  T‐cell subpopulations in the blood and skin of patients with psoriasis , 1984, The British journal of dermatology.

[30]  W. Cunliffe,et al.  Keratin gene expression during the resolution of psoriatic plaques: effect of dithranol, PUVA, etretinate and hydroxyurea regimens , 1989, The British journal of dermatology.

[31]  N. Lowe,et al.  Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. , 1989, Journal of the American Academy of Dermatology.

[32]  H. Valdimarsson,et al.  Epidermal T lymphocytes and HLA‐DR expression in psoriasis , 1984, The British journal of dermatology.

[33]  R. Steinman,et al.  Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. , 1986, The New England journal of medicine.

[34]  G. Volden Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. , 1992, Acta dermato-venereologica.

[35]  L. Nanney,et al.  Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. , 1986, The Journal of investigative dermatology.

[36]  A. Giannetti,et al.  1,25-dihydroxyvitamin D3, transforming growth factor β1, calcium, and ultraviolet B radiation induce apoptosis in cultured human keratinocytes , 1997 .

[37]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[38]  Irene M. Leigh,et al.  Keratins (Kl6 and Kl7) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro , 1995 .

[39]  M. Duvic,et al.  Response of psoriasis to a new topical retinoid, AGN 190168. , 1994, Journal of the American Academy of Dermatology.